Drugs / Sulodexide
Sulodexide
also known as
KRX-101 · KRX-101 (sulodexide) · SLX · Sulodexida · Vessel · Vessel due f · Vessel due F (Alfasgima SpA, Italy)
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00583427 | Dec 2007 → Dec 2009 | dense deposit disease | University of Iowa | Withdrawn | No outcome recorded |
| Phase 35 trials · 1 missed | ||||||
| Phase 3 | NCT06982196 | Apr 2025 → Jun 2026 overdue | psoriasis | Xijing Hospital | Enrolling by invitation | No outcome recorded |
| Phase 3 | NCT05005052 | Nov 2021 → Dec 2023 | chronic venous insufficiency | Value Outcomes Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT03370705 | Jan → Dec 2019 | peripheral arterial occlusive disease 1 | Alfa Wassermann Tunisia | Unknown | No outcome recorded |
| Phase 3 | NCT00462202 | Apr 2007 → Mar 2008 | diabetic kidney disease | Keryx Biopharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00130208 | Aug 2005 → Jan 2008 | diabetic kidney disease | Keryx Biopharmaceuticals | Completed | Missed primary |
| Phase 45 trials | ||||||
| Phase 4 | NCT05252923 | Apr → Sep 2022 | COVID-19, thrombotic disease | Pirogov Russian National Research Medical University | Terminated | No outcome recorded |
| Phase 4 | NCT03504566 | Nov 2017 → Jun 2019 | diabetic kidney disease | Steno Diabetes Center Copenhagen | Withdrawn | No outcome recorded |
| Phase 4 | NCT02512601 | Sep 2015 → Feb 2017 | post-thrombotic syndrome | Bama GeVe, S.L.U. | Terminated | No outcome recorded |
| Phase 4 | NCT01316068 | Mar 2011 → Aug 2012 | diabetic kidney disease, proteinuria | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 4 | NCT00130312 | Aug 2005 → Mar 2008 | diabetic kidney disease | Keryx Biopharmaceuticals | Terminated | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT05654233 | Feb → Aug 2023 | chronic venous insufficiency, peripheral vascular disease, varicose disease | Chengdu University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| — | NCT04180137 | Nov 2019 → Dec 2020 | chronic venous insufficiency | State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 2 | NCT02737670 Comparator | Aug 2014 → Mar 2017 | tinnitus | St Joseph University, Beirut, Lebanon | Completed | No outcome recorded |
| Phase 2 | NCT01295775 Comparator | Feb 2009 → Apr 2011 | background diabetic retinopathy | Ajou University School of Medicine | Completed | No outcome recorded |
| Phase 2/3 | NCT04483830 Comparator | Jun → Aug 2020 | COVID-19 | Clinedem | Completed | No outcome recorded |
| Phase 3 | NCT05371925 Comparator | Jun 2023 → Feb 2024 | post-COVID-19 disorder, thrombotic disease | Centro Medico del Noroeste | Completed | No outcome recorded |
| Phase 3 | NCT04257487 Comparator | Dec 2020 → Dec 2025 overdue | venous thromboembolism | Arianna Anticoagulazione Foundation | Recruiting | No outcome recorded |
| Phase 3 | NCT01000545 Comparator | Nov 2009 → Jan 2011 | chronic kidney disease | Corbridge Group Philippines, Inc. | Unknown | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sulodexide | “This study compares the efficacy and safety of sulodexide (Vessel) to placebo in patients with chronic venous disease of the lower extremities.” NCT05005052 ↗18“After surgical intervention the active treatment group will receive sulodexide 250 lipasemic units (LSU) bid for 30 days.” NCT04180137 ↗ |
| Known as | KRX-101 | “An Open Label Tolerability and Safety Study of KRX-101 (Sulodexide Gelcaps) for the Treatment of Type 2 Diabetic Nephropathic Patients With Persistent Microalbuminuria in...” NCT00462202 ↗ |
| Known as | KRX-101 (sulodexide) | “KRX-101 (sulodexide)” NCT00583427 ↗ |
| Known as | SLX | “SLX” NCT01000545 ↗ |
| Known as | Sulodexida | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108086 ↗ |
| Known as | Vessel | “This study compares the efficacy and safety of sulodexide (Vessel) to placebo in patients with chronic venous disease of the lower extremities.” NCT05005052 ↗ |
| Known as | Vessel due f | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108086 ↗ |
| Known as | Vessel due F (Alfasgima SpA, Italy) | “Vessel due F (Alfasgima SpA, Italy)” NCT05371925 ↗ |
| Modality | Other / unclassified | “Sulodexide, a heterogenous group of sulfated glycosaminoglycans” PMID 21872376 ↗ Aug 2011 |
| Route | Oral | “administered orally twice a day.” NCT00130208 ↗ |